APUS — Apimeds Pharmaceuticals US, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1894525 ·
Last close
$1.42
Market Cap
$17.86M
52W High
$21.00
52W Low
$1.24
ADV30
246,512
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -7,040,051 | -1,155,292 | 164,183,736 | 1,636,655 | 10,835,909 |
| Sep 2025 | 0 | — | -1,844,239 | -1,781,255 | 9,250,036 | 6,986,617 | 1,089,384 |
| Jun 2025 | 0 | — | -2,663,904 | -2,662,193 | 10,546,681 | 8,735,323 | 809,002 |
| Mar 2025 | 0 | — | -364,368 | -402,397 | 259,904 | 250,342 | 2,020,422 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,925,777
Investing CF
$-10,046,982
Financing CF
$20,619,327
CapEx
$-43,964
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-10,393,061
Inventory
—
Receivables
—
ST Investments
$2,000,000
EBIT TTM
$-5,718,126
Pretax Income TTM
$-6,001,137
Interest Exp TTM
$283,011
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,912,562 | -6,001,137 | 164,183,736 | 10,835,909 | — | -8,925,777 |
| Dec 2024 | 0 | -1,275,095 | -1,389,990 | 13,057 | 1,371,178 | — | -733,526 |
| Dec 2023 | 0 | -747,436 | -777,694 | 422,076 | 390,207 | — | -627,790 |
| Dec 2022 | 0 | -639,529 | -668,666 | 6,171 | 719,777 | — | -448,167 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HCWB | HCW Biologics Inc. | $17.64M | $2.62 | — |
| LPCN | Lipocine Inc. | $18.63M | $2.26 | — |
| XCUR | EXICURE, INC. | $17.04M | $2.67 | — |
| NCEL | NewcelX Ltd. | $16.96M | $3.15 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $19.13M | $0.70 | — |
News headlines (Yahoo Finance, 1h cache)
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
2026-05-05 18:07 · Yahoo
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
2026-03-24 12:30 · Yahoo
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
2026-02-11 21:51 · Yahoo
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
2025-11-10 15:00 · Yahoo
Apimeds Pharmaceuticals says "I love my Ducks" with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
2025-10-14 07:02 · Yahoo
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
2025-09-15 22:24 · Yahoo
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
2025-09-12 01:54 · Yahoo
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
2025-08-25 18:11 · Yahoo
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
2025-07-15 21:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.